ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025
ADC Therapeutics announced they will provide an update on the LOTIS-7 Phase 1b open-label clinical trial on December 3, 2025, via a corporate webcast at 8:
00 a.m. EST.
The LOTIS-7 trial is evaluating the safety and efficacy of ZYNLONTA (loncastuximab tesirine) in combination treatments for certain cancers.
Earlier data from the LOTIS-7 trial were presented at the European Hematology Association 2025 Congress in June 2025.
The trial is multi-center, multi-arm, designed to assess anti-cancer activity alongside safety.
A fuller and more mature data update for the trial was anticipated during the second half of 2025, with preliminary data shared in the second quarter of 2025.